NOI - Next Generation Sequencing Services for Detection of Somatic Genetic Mutations

Summary (Newest Update)

Background The National Heart, Lung, and Blood Institute (NHLBI) intends to award a sole source purchase order to Genomic Testing Cooperative (GTC) for Next Generation Sequencing (NGS) services. These services will support clinical research by analyzing patient samples to detect somatic genetic mutations associated with bone marrow failure syndromes. GTC is the only vendor identified that can meet all of the Government’s requirements, including a sequencing panel that includes critical genes necessary for diagnosing conditions such as VEXAS syndrome. Work Details The contractor shall provide Next Generation Sequencing services capable of analyzing a panel of approximately 302 genes associated with hematologic neoplasms and related conditions. Services shall include: - Processing of patient-derived samples (e.g., plasma, fresh cells, or paraffin-embedded tissue) - Sequencing of coding DNA regions - Generation of detailed reports identifying genetic mutations. The required services must meet the following minimum technical requirements: - Capability to analyze approximately 302 genes associated with hematologic disorders - Ability to isolate nucleic acids from multiple sample types - Massive parallel sequencing of coding DNA regions - Detection of mutations including insertions, deletions, and structural variants - Fragment length analysis capability for specific genes - Ability to process low DNA input quantities - Secure delivery of results via electronic reporting system - Turnaround time of approximately 7–10 days after receipt of samples. Approximately 16 samples will be processed. Period of Performance The period of performance will continue until all samples (approximately 16) have been processed. Place of Performance Services shall be performed at the contractor’s facility.